Search research articles
Contact Us
Filters
Showing results (81-90 of 91) with videos related to
Page
of 10
Sort By:
Journal of Molecular and Cellular Cardiology
|
December 31, 2002
Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes
Karin Macfelda, Thomas W Weiss, Christoph Kaun, et al.
International Journal of Cardiology
|
May 2, 2024
Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study
Paulus Kirchhof, Ameet Bakhai, Carlo de Asmundis, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)
|
December 13, 2018
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study
Raffaele De Caterina, Peter Kelly, Pedro Monteiro, et al.
Stroke
|
December 14, 2004
Can a commercial diagnostic ultrasound device accelerate thrombolysis? An in vitro skull model
Stefan Pfaffenberger, Branka Devcic-Kuhar, Christian Kollmann, et al.
BMC Cardiovascular Disorders
|
July 14, 2019
Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)
Raffaele De Caterina, Peter Kelly, Pedro Monteiro, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
July 26, 2022
Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care
Paulus Kirchhof, Ladislav Pecen, Ameet Bakhai, et al.
Cardiovascular Research
|
September 23, 2003
Glycoprotein 130 ligand oncostatin-M induces expression of vascular endothelial growth factor in human adult cardiac myocytes
Thomas W Weiss, Walter S Speidl, Christoph Kaun, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
August 14, 2020
Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study
Joris R de Groot, Thomas W Weiss, Peter Kelly, et al.
European Heart Journal
|
October 30, 2016
Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis
Sigrun Halvorsen, Robert F Storey, Bianca Rocca, et al.
European Heart Journal
|
July 12, 2015
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis
Felicita Andreotti, Bianca Rocca, Steen Husted, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 91) with videos related to
Sort By:
Page
of 10
Journal of Molecular and Cellular Cardiology
|
December 31, 2002
Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes
Karin Macfelda, Thomas W Weiss, Christoph Kaun, et al.
International Journal of Cardiology
|
May 2, 2024
Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study
Paulus Kirchhof, Ameet Bakhai, Carlo de Asmundis, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)
|
December 13, 2018
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study
Raffaele De Caterina, Peter Kelly, Pedro Monteiro, et al.
Stroke
|
December 14, 2004
Can a commercial diagnostic ultrasound device accelerate thrombolysis? An in vitro skull model
Stefan Pfaffenberger, Branka Devcic-Kuhar, Christian Kollmann, et al.
BMC Cardiovascular Disorders
|
July 14, 2019
Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)
Raffaele De Caterina, Peter Kelly, Pedro Monteiro, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
July 26, 2022
Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care
Paulus Kirchhof, Ladislav Pecen, Ameet Bakhai, et al.
Cardiovascular Research
|
September 23, 2003
Glycoprotein 130 ligand oncostatin-M induces expression of vascular endothelial growth factor in human adult cardiac myocytes
Thomas W Weiss, Walter S Speidl, Christoph Kaun, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
August 14, 2020
Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study
Joris R de Groot, Thomas W Weiss, Peter Kelly, et al.
European Heart Journal
|
October 30, 2016
Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis
Sigrun Halvorsen, Robert F Storey, Bianca Rocca, et al.
European Heart Journal
|
July 12, 2015
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis
Felicita Andreotti, Bianca Rocca, Steen Husted, et al.
Page
of 10